GRI Bio reports positive interim safety results from Phase 2a IPF study; IDMC recommends continuation

GRI Bio, Inc.

IDMC recommends study continue after no safety concerns in first 24 patients evaluated at 6 weeks.
GRI-0621 safe and well-tolerated; no adverse events related to hyperlipidemia (LDL, HDL, TG).
No clinically meaningful changes in HDL, LDL, or TG levels; all subjects within protocol ranges.
Interim biomarker data expected July 2025; topline results from Phase 2a study expected Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.